Table 3.
Parameters to be considered in developing a PRP classification system.
| Parameters | Differentials | Options |
|---|---|---|
| Biological Product Allocation | Autologous Allogeneic |
Buffy Coat Partial Buffy Coat Fresh Frozen/Thawed Platelet Lysate Umbilical cord blood |
| Preparation Technology | Gravitational Centrifugation Blood Salvage Blood Separators Plasmapheresis |
Preparation time Spin-Cycles G-Forces |
| Anticoagulation | ACD-A EDTA SC Heparin |
|
| Platelet dosing | Concentration ranges | 0–500 × 106/mL 500–1000 × 106/mL 1000–1500 × 106/mL >1500 × 106/mL |
| Leukocytes Presence | Yes No |
Neutrophils–Monocytes–Lymphocytes Poor–Poor |
| RBC | Yes No |
Hematocrit (range) |
| Delivery Form | Liquid Coagulated |
Partial Full |
| Fibrin Matrix | Yes No |
Concentration levels Content specific |
| Activation | Yes No |
CaCl Thrombin Collagen Electrical Freeze Sonication Light |
| Additives | Biodegradable Scaffolds Matrices Autologous Biologics Non-autologous |
Dexamethasone—HA—cPPP—BMAC—Adipose—Bone-Exosomes—Amniotic -Wharton Jelly—A-Cell Protein Preparations— Antibiotics—Pain medication |
| Administration Routes | Topical IV Tissue structure Intraosseous |
Soft tissue: Tendon—Ligament—Muscle—Scar Intradiscal—Epidural—Intrathecal—Intra-Articular |
Abbreviations: G-Force: gravitational force, ACD-A: Anticoagulant Citrate Dextrose Solution-Solution A, EDTA: Ethylenediaminetetraacetic acid, SC: sodium citrate, CaCl: calcium chloride, HA: Hyaluronic Acid, cPPP: concentrate platelet poor plasma, BMAC: bone marrow concentrate, IV: intravenous.